Heinz Hillen

Summary

Affiliation: Abbott Laboratories
Country: USA

Publications

  1. doi request reprint Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies
    Heinz Hillen
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott, d 67061 Ludwigshafen, Germany
    J Neurosci 30:10369-79. 2010
  2. doi request reprint Abeta-globulomers are formed independently of the fibril pathway
    Gerald P Gellermann
    Neuroscience Discovery Research, Abbott GmbH and Co KG, Knollstrasse, d 67061 Ludwigshafen, Germany
    Neurobiol Dis 30:212-20. 2008
  3. doi request reprint Amyloid beta oligomers (A beta(1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents
    Volker Nimmrich
    Neuroscience Discovery, Global Pharmaceutical Research and Development, Abbott, d 67061 Ludwigshafen, Germany
    J Neurosci 28:788-97. 2008

Collaborators

Detail Information

Publications3

  1. doi request reprint Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies
    Heinz Hillen
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott, d 67061 Ludwigshafen, Germany
    J Neurosci 30:10369-79. 2010
    ..Our findings demonstrate that selective reduction of Abeta oligomers by immunotherapy is sufficient to normalize cognitive behavior and synaptic deficits in APP transgenic mice...
  2. doi request reprint Abeta-globulomers are formed independently of the fibril pathway
    Gerald P Gellermann
    Neuroscience Discovery Research, Abbott GmbH and Co KG, Knollstrasse, d 67061 Ludwigshafen, Germany
    Neurobiol Dis 30:212-20. 2008
    ..We hypothesize that a conformational switch of A beta is decisive for either fibril formation or alternatively and independently A beta-globulomer formation...
  3. doi request reprint Amyloid beta oligomers (A beta(1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents
    Volker Nimmrich
    Neuroscience Discovery, Global Pharmaceutical Research and Development, Abbott, d 67061 Ludwigshafen, Germany
    J Neurosci 28:788-97. 2008
    ..Selective enhancement of the P/Q calcium current may provide a promising strategy in the treatment of Alzheimer's disease...